Skin Affecting Patents (Class 514/18.6)
-
Publication number: 20110081323Abstract: Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described.Type: ApplicationFiled: September 20, 2010Publication date: April 7, 2011Inventors: Don Kleinsek, Adriana Soto
-
Publication number: 20110081401Abstract: The present invention relates to masks for dermal treatment or “patches”, based on a vegetal matrix, particularly red algae (Chondrus crispus) extract rich in polymeric thickeners. The invention relates also to compositions, in particular cosmetic and dermopharmaceutical formulations, to the process for their industrial preparation and to their use in cosmetic and pharmaceutical applications.Type: ApplicationFiled: April 9, 2009Publication date: April 7, 2011Applicant: BIOPHIL ITALIA S.P.A.Inventors: Federico Panzieri, Giacomo Santus
-
Publication number: 20110081344Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: ApplicationFiled: November 10, 2010Publication date: April 7, 2011Inventors: Wayne R. Kindsvogel, Stavros Topouzis
-
Publication number: 20110070237Abstract: Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium.Type: ApplicationFiled: September 1, 2010Publication date: March 24, 2011Applicant: CALCIMEDICA, INC.Inventors: Jack Roos, Kenneth A. Stauderman, Gonul Velicelebi, Paul J. Digregorio, Kari Lynn Ohlsen
-
Patent number: 7910542Abstract: The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.Type: GrantFiled: September 26, 2008Date of Patent: March 22, 2011Assignee: UT-Battelle, LLCInventor: Cymbeline T. Culiat
-
Publication number: 20110059173Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.Type: ApplicationFiled: August 30, 2010Publication date: March 10, 2011Applicant: MUSC Foundation for Research DevelopmentInventors: Robert GOURDIE, Gautam Ghatnekar, Jane Jourdan
-
Publication number: 20110059885Abstract: The method of the invention relates to an OmCI polypeptide or a polynucleotide encoding an OmCI polypeptide for the treatment of a disease or condition mediated by a leukotriene or hydroxyeicosanoid.Type: ApplicationFiled: February 5, 2009Publication date: March 10, 2011Inventors: Susan Lea, Miles Nunn, Pietro Roversi
-
Publication number: 20110059896Abstract: The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions.Type: ApplicationFiled: November 23, 2009Publication date: March 10, 2011Inventors: Mark William James FERGUSON, Georg Brunner
-
Publication number: 20110059897Abstract: A therapeutic method for treating a skin wound involving administering to a patient in need thereof a composition containing pharmaceutically effective amounts of the following components: (1) a peptide consisting of the amino acid sequence represented by Ser-Ser-Ser-Arg (SEQ ID NO: 1) or pharmaceutically acceptable salts thereof and (2) a peptide consisting of the amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 2) or substance P or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable additive.Type: ApplicationFiled: July 29, 2010Publication date: March 10, 2011Applicants: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Teruo Nishida, Makoto Inui, Masatsugu Nakamura
-
Patent number: 7901669Abstract: The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to activate a heteromeric receptor comprising OSMR? as a subunit, for the preparation of a composition for activating in vitro and/or in vivo keratinocyte migration and/or the expression of anti-microbial peptides by the keratinocytes. In particular, the invention concerns the use of OSM and/or IL-17 and/or TNF? and/or IL-31, or agonists thereof, for the preparation of cosmetic or dermatologic compositions.Type: GrantFiled: December 15, 2005Date of Patent: March 8, 2011Assignees: Universite d'Angers, Universite de Poitiers, Bioalternatives SASInventors: Jean-Claude Lecron, Hughes Gascan, Franck Morel, Sylvie Chevalier, François-Xavier Bernard, Katia Boniface, Caroline Diveu
-
Publication number: 20110052493Abstract: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favourable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.Type: ApplicationFiled: November 9, 2009Publication date: March 3, 2011Applicant: CREABILIS THERAPEUTICS S.P.A.Inventors: Silvano FUMERO, Luisa Bertarione Rava Rossa, Domenico G. Barone, Lila Drittanti, Thierry Guyon, Gilles Borrelly, Barbara Canepa, Chiara Lorenzetto
-
Publication number: 20110052514Abstract: The invention relates to cosmetic or therapeutic compositions that contain hydrolysed yeast proteins as an active ingredient, to the use of said cosmetic or therapeutic compositions, and to a method for cosmetic treatment.Type: ApplicationFiled: February 11, 2009Publication date: March 3, 2011Applicant: LESAFFRE ET COMPAGNIEInventors: Peter Jüsten, Dominique Marie Noelle Borreill, William Marques
-
Publication number: 20110053860Abstract: The invention relates to compositions and methods for enhancing bone healing, bone formation and wound healing. More specifically, it relates to the use of cyclooxygenase 2 (COX-2) following bone fracture, orthopaedic procedure or wound infliction to enhance healing.Type: ApplicationFiled: September 3, 2009Publication date: March 3, 2011Inventor: J. Patrick O'Connor
-
Publication number: 20110052519Abstract: The invention relates to peptide derivatives of general formula (I): R1-AA1-AA2-AA3-AA4-R2??(I) their stereoisomers, mixtures thereof, and their cosmetically or pharmaceutically acceptable salts, a method for obtaining them, cosmetic or pharmaceutical compositions containing them and their use for the treatment, care and/or cleansing of those conditions, disorders and/or pathologies of the skin, mucosae, scalp and/or nails resulting from microorganism proliferation or being at risk of microorganism proliferation.Type: ApplicationFiled: January 30, 2009Publication date: March 3, 2011Inventors: Cristina Carreño Serraïma, Wim Van Den Nest, Ana Sempere, Antonio Ferrer Montiel, Juan Cebrian Puche, Núria Almiñana Domenech, David Panyella Costa, José Ginestar Gonzalez
-
Publication number: 20110053833Abstract: At least one embodiment of the present invention relates to new peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars.Type: ApplicationFiled: October 17, 2008Publication date: March 3, 2011Inventors: Inger Mattsby-Baltzer, Lars Hansson, Lars Baltzer, Gunnar Dolphin
-
Publication number: 20110044974Abstract: The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-?3 aminoacyl residue, and also their uses in pharmaceutical compositions or for the diagnosis of pathologies wherein the aforesaid peptides or parent proteins are involved.Type: ApplicationFiled: June 11, 2004Publication date: February 24, 2011Inventors: Michele Baudy Floc'h, Olivier Busnel, Sylviane Muller
-
Publication number: 20110044905Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia compromised lactation conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.Type: ApplicationFiled: March 30, 2009Publication date: February 24, 2011Applicant: Ferring B.V.Inventors: Sudar Alagarsamy, Robert Galyean, Kazimierz Wisniewski, Claudio Schteingart
-
Publication number: 20110045041Abstract: The present invention relates to methods and compositions for the delivery of cosmetics and medicants. In some embodiments, the invention relates to compositions comprising both hydrophobic and hydrophilic polymers. In preferred embodiments, the invention relates to the delivery of peptides, small molecules and other bioactive compounds using the compositions and methods disclosed herein.Type: ApplicationFiled: March 26, 2009Publication date: February 24, 2011Inventors: Nevenka Golubovic-Liakopoulos, Bhavdeep Shah, Erik Andersen
-
Publication number: 20110038853Abstract: The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in particular Kif13A, or of the interaction between a sub-unit of AP-1 adaptor complex and said kinesin, as well as the use of same to manufacture a drug intended for the treatment of pigmentary disorders and as a depigmentation agent.Type: ApplicationFiled: April 21, 2009Publication date: February 17, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIEInventors: Graca Raposo, Cédric Delevoye, Danièle Tenza, Ilse Hurbain
-
Publication number: 20110038946Abstract: A biodegradable polyurethane scaffold, comprising at least one polyisocyante, polyisocyanate prepolymer, or both, at least one polyester polyol, at least one catalyst, wherein the density of said scaffold is from about 50 to about 250 kg m-3 and the porosity of the scaffold is greater than about 70 (vol %) and at least 50% of the pores are interconnected with another pore, and wherein the scaffold incorporates at least one biologically active component in powder form.Type: ApplicationFiled: September 5, 2008Publication date: February 17, 2011Inventors: Scott A. Guelcher, Andrea E. Hafeman
-
Publication number: 20110034393Abstract: The invention relates to cosmetic or dermatological compositions containing mannoproteins as an active ingredient and/or adjuvant, to the use of said cosmetic or dermatological compositions and to cosmetic treatment methods.Type: ApplicationFiled: September 23, 2008Publication date: February 10, 2011Applicant: LESAFFRE ET COMPAGNIEInventors: Peter Jüsten, Dominique Marie Noëlle Borreill
-
Publication number: 20110033507Abstract: The invention concerns polypeptides of the general formula (I): A-(Xaa)n-Lys-X-Lys-B wherein: i) A is —NH2, NH3+, or NH-D (D is an acyl group being biotin or an alkyl chain (C2-C22)), H) B is H, O? OR1 or NR2R3 and R1, R2 and R3 independently either: H or an alkyl chain (C1-C24), iii) (Xaa)n is an amino acid chain including any amino acid natural or not, excluding arginine and lysine, iv) “n” is between 0-3, and v) X is either a chain of two any amino acids (Xaa1Xaa2), which may be the same or different, excluding arginine, lysine and excluding Xaa1Xaa2=Thr-Thr, Gly-His and Glu-His, or X is a spacer selected among beta-alanyl, 5-amino-valeroyl, 4-amino-cyclohexanoyl, 4-amino-butyroyl, 6-amino-caproyl and derivatives thereof. More particularly, the invention concerns polypeptides of formula (I) wherein “n” is 0 and with the formula: A-Lys-X-Lys-B; A, X and B being defined herein. Compositions containing at least one of said polypeptides and their use.Type: ApplicationFiled: February 16, 2006Publication date: February 10, 2011Applicant: SEDERMAInventors: Karl Lintner, Olivier Peschard, Philippe Mondon, Claire Mas Chamberlin
-
Publication number: 20110033521Abstract: Molecules and compositions including same for the isolation of MCP-1 and treatment of CCR2/MCP-1 associated diseases.Type: ApplicationFiled: April 10, 2006Publication date: February 10, 2011Applicant: Rappaport Family Institute for Research in the Medical SciencesInventors: Nathan Karin, Gizi Wildbaum, Yaniv Zohar, Liat Izhak, Uri Weinberg
-
Publication number: 20110035817Abstract: The present invention relates to a splice variant of SIVA, SIVA3, and to its use.Type: ApplicationFiled: February 9, 2009Publication date: February 10, 2011Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: David Wallach, Parameswaran Ramakrishnan, Andrei Kovalenko
-
Publication number: 20110027364Abstract: A method of producing a soybean-based biomaterial which is suitable for use in a biomedical product, the method comprising: defatting soy flour; either prior to or at the same time as, performing a solvent extraction; to produce a biomaterial comprising variable levels of soy proteins, carbohydrates and isoflavones. The resulting biomaterials have a range of biomedical uses and are particularly desirable because of their isoflavone content. Examples of biomedical products containing the biomaterials include wound dressings; scaffolds for tissue engineering; fillers or implants for use in surgery; temporary barriers for use in dental or surgical procedures or to prevent post-surgical tissue adherence; carriers for the delivery of drugs, bioactive peptides or plasmids; anti-inflammatory agents; coatings for wound dressings or for dental, medical, surgical or veterinary devices or implants; and compositions for soothing skin or gum irritation.Type: ApplicationFiled: November 26, 2008Publication date: February 3, 2011Applicant: UNIVERSITY OF BRIGHTONInventors: Luigi Ambrosio, Luigi Nicolais, Jonathan Peter Salvage, Matteo Santin, Guy Standen
-
Publication number: 20110028403Abstract: A non-natural HSP70 activating region that activates dendritic cells. Polypeptides that bind to the HSP70 activating region can be used to treat autoimmune diseases, such as vitiligo, by binding to HSP70 and preventing HSP70 form activating dendritic cells. The HSP70 binders can be constructed in the form of fusions proteins with a trimerizing structural element that may associate to form a trimeric complex. Pharmaceutical compositions and methods for treating vitiligo using the HSP70 binding proteins, fusion proteins and complexes.Type: ApplicationFiled: March 12, 2010Publication date: February 3, 2011Inventors: ISABELLE CAROLINE LE POOLE, JOSEPHUS DIRK NIELAND, THOR LAS HOLTET
-
Publication number: 20110028404Abstract: The present invention relates to a composition for promoting stem cell proliferation which contains a vegetable peptone. More specifically, this invention relates to: a serum-free composition for culturing stem cells which contains a vegetable peptone; a composition for improving skin condition containing the vegetable peptone as an active ingredient; and a composition for improving skin condition containing a culture medium as an active ingredient in which cultured stem cells are removed after being cultured in a serum-free composition medium for stem cell culture containing the vegetable peptone. Since the disclosed serum-free composition for culturing stem cells does not need the use of expensive animal serum, the manufacturing cost can be remarkably lowered. Also the use of anima serum in the medium can basically prevent contamination material caused by the use of animal serum.Type: ApplicationFiled: March 19, 2009Publication date: February 3, 2011Applicant: Bio Spectrum ,Inc.Inventors: Deok Hoon Park, Jienny Lee, Jong Sung Lee
-
Publication number: 20110028398Abstract: The present invention provides methods for treating and/or limiting fibrotic disorders and/or treating or limiting scars selected from the group consisting of keloids and hypertrophic scars comprising administering to an individual in need thereof an amount effective to treat and/or limit scars selected from the group consisting of keloids and hypertrophic scars of a polypeptide comprising an HSP20-related polypeptide.Type: ApplicationFiled: July 10, 2007Publication date: February 3, 2011Applicant: The Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State UniversiInventors: Luciana Biagini Lopes, Elizabeth J. Furnish, Charles Robert Flynn, Padmini Komalavilas, Alyssa Panitch, Colleen M. Brophy
-
Publication number: 20110020437Abstract: The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X1X2X3X3?X1?? (SEQ ED NO: 1), wherein X1 and X1?? are independently selected from the group of basic amino acids, X2 is a lipophilic amino acid and X3 and X3? are independently selected from the group of uncharged amino acids; and wherein the oligopeptidic compound is further characterised by at least one of the following: (i) the oligopeptidic compound comprises at least one signal sequence; (ii) the PCNA interacting motif is [K/R]-F-{LIV]-[LIV]-[K/R] (SEQ ID NO. 27). Particularly the therapy may be the treatment of a disorder or condition where it is desirable to inhibit the growth of cells, for example a hyperproliferative disorder, or a treatment which involves cytostatic therapy e.g. myeloablation.Type: ApplicationFiled: February 20, 2009Publication date: January 27, 2011Applicant: APIM THERAPEUTICS ASInventors: Marit Otterlei, Per Arne Aas, Emadoldin Feyzi
-
Publication number: 20110021418Abstract: Haptoglobin (Hp) removes cell-free Hemoglobin (Hb), with different physiological effects depending on the particular Hp polymer. We propose that material enriched for alpha 1 chain Hp polymeric forms, such as those made from Cohn fraction V precipitate, will be more suitable for the treatment of certain diseases benefiting from both an antioxidant and anti-inflammatory component, such as for hemolytic disease. Material enriched for alpha-2 chain Hp polymeric forms, made for example from Cohn fraction IV precipitate, will be more suitable for treatment of diseases where an angiogenic, and/or inflammatory affect, and/or limited extravasation is desirable.Type: ApplicationFiled: September 20, 2010Publication date: January 27, 2011Applicant: NHS BLOOD AND TRANSPLANTInventors: JOAN DALTON, ADRIAN PODMORE
-
Publication number: 20110020375Abstract: Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.Type: ApplicationFiled: April 1, 2010Publication date: January 27, 2011Inventors: Keting Chu, Lewis T. Williams, Justin G. P. Wong, Kevin Hestir, Amy L. Tsui Collins, Ernestine Lee
-
Publication number: 20110008455Abstract: This invention relates to crosslinked protein nanoparticles and a method for producing the same. The method comprises the preparation and nanonization (i.e., size reduction to the nanoscale) of protein nanoparticle precursor materials—i.e., crosslinked proteins of the micron or greater size—via mechanical or hydrodynamic shear, mechanical crushing, sonic cavitation and/or hydrodynamic cavitation.Type: ApplicationFiled: July 6, 2010Publication date: January 13, 2011Applicant: SABANCI UNIVERSITYInventor: Alpay Taralp
-
Publication number: 20110009310Abstract: Soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in chick and mouse and thereby inhibits human tumor growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble non glycosylated CD44 recombinant proteins as a novel class of angiogenesis inhibitors based on targeting of vascular cell surface receptor. A method of block of angiogenesis and treatment of human tumors using recombinant CD44 proteins as well as their analogues is disclosed. As a further embodiment of the invention, methods for screening for new drug targets using CD44 recombinant proteins and their analogues are presented.Type: ApplicationFiled: March 5, 2010Publication date: January 13, 2011Applicant: Celecure AsInventors: Staffan Stromblad, Priit Kogerman, Taavi Pall
-
Publication number: 20110009332Abstract: The present disclosure relates to compositions and methods for treating wounded skin and/or increasing the mechanical strength of wounded skin through the administration of an effective amount of a proteasome inhibitor to such wounded skin.Type: ApplicationFiled: June 10, 2010Publication date: January 13, 2011Applicant: SOUTHWEST RESEARCH INSTITUTEInventor: Jorge Gianny ROSSINI
-
Publication number: 20110002969Abstract: Peptides of general formula (I): R1AA1-AA2-AA3-AA4-R2 stereoisomers thereof, mixtures thereof or the cosmetically or pharmaceutically acceptable salts thereof, a method for obtaining them, cosmetic or pharmaceutical compositions containing them, and their use for the treatment and/or care of those conditions, disorders and/or pathologies of the skin, mucosae and/or scalp resulting from matrix metalloproteinases (MMP) overexpression or an increase in the MMP activity.Type: ApplicationFiled: February 27, 2009Publication date: January 6, 2011Applicant: LIPOTEC, S.A.Inventors: Cristina Carreno Serraima, Wim Van Den Nest, Juan Cebrian Puche, Nuria Alminana Domenech, Antonio Ferrer Montiel, Nuria Garcia Sanz
-
Publication number: 20110002880Abstract: The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable ?-sheet structure in an aqueous solution in the presence of a monovalent ion. The material for wound healing and skin reconstruction of the present invention is capable of healing a wound area of mammals quicker than spontaneous recovery without leaving any scars, wherein the material has no potential risk of infectious disease such as virus transmission.Type: ApplicationFiled: December 4, 2008Publication date: January 6, 2011Applicant: 3-D MATRIX, LTD.Inventors: Kentaro Takamura, Jiro Takei
-
Publication number: 20100322948Abstract: The present invention relates to the identification and use of bone morphogenetic protein (BMP)-binding domains of members of the repulsive guidance molecule (RGM) protein family, and polypeptide fragments and fusion proteins derived therefrom. The domains, i.e., peptide fragments and fusion proteins, according to the invention are suitable as agents for the active or passive immunization of individuals, or as diagnostic and therapeutic agents for use for diseases or medical conditions in whose origin or progression a member of the RGM family and a cellular receptor associated with this molecule, such as neogenin and/or BMP in particular, is involved. The invention further relates to monoclonal and polyclonal antibodies directed against the binding domains according to the invention, and against the polypeptides derived therefrom, and to methods for producing the polypeptides, fusion proteins, and antibodies according to the invention.Type: ApplicationFiled: September 8, 2008Publication date: December 23, 2010Applicant: ABBOTT GMBH & CO. KGInventors: Bernhard Mueller, Gregor Schaffar, Axel Meyer, Martin Schmidt
-
Publication number: 20100317590Abstract: The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype.Type: ApplicationFiled: December 7, 2007Publication date: December 16, 2010Inventors: Vincent Hearing, Yuji Yamaguchi, Thierry Passeron
-
Publication number: 20100317591Abstract: This invention provides a method of treating a subject suffering from a dermatologic condition, including, inter alia, psoriasis, contact dermatitis, and seboreic dermatitis, the method includes the step of administering to a subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, in an amount effective to treat the subject suffering from a dermatologic condition.Type: ApplicationFiled: June 22, 2010Publication date: December 16, 2010Inventor: Saul Yedgar
-
Publication number: 20100311666Abstract: The present invention relates to the use, in cosmetics and in therapeutics, of at least one antimicrobial protein belonging to the ribonuclease family, ribonuclease 7, or of polypeptides derived from said protein, notably as a marker for evaluating the condition of the epidermis. It further relates to the use of at least one polypeptide according to the invention, of at least one nucleic acid sequence coding for a polypeptide according to the invention, or of at least one agent that modulates the expression or the activity, notably biological, of said polypeptide or of its interaction with an element of the extracellular matrix, for the preparation of compositions intended for the prevention and/or treatment of skin disorders.Type: ApplicationFiled: November 16, 2007Publication date: December 9, 2010Applicant: L'OREALInventors: Mark Donovan, Dominique Bernard, Isabelle Castiel, Veronique Chaussade
-
Publication number: 20100311645Abstract: The Present invention relates to molecules isolated from the nucleic acid that encodes spider web proteins or fragments of these or other derivatives of these. The invention also refers to a chimerical gene and an expression vector containing molecules isolated from the nucleic acid that codes for proteins related to the webs of Nephilengys, Cruentata, Avicularia Juruensis and Parawixia Bistriata spiders. Another embodiment of the present invention are transformed cells containing a chimerical gene or an expression vector of the present invention. Yet another embodiment of the present invention relates to a method for obtaining genetically modified organisms containing inventive chimerical genes or expression vectors and a method for obtaining recombinant proteins from the silks of Nephilengys, Cruentata, Aviculana Juruensis and Parawixia Bistriata spiders. Finally, the invention describes products, such as biofilaments and compositions, using the recombinant proteins of the present invention.Type: ApplicationFiled: March 13, 2008Publication date: December 9, 2010Applicants: Empresa Brasileira de Pesquisa Agropecuaria- EMBRAPA, Fundacao Universidade de BrasiliaInventors: Elibio Leopoldo Rech Filho, Natalia Cristina Verza Ferreira, Giovanni Rodrigues Vianna, Felipe Rodrigues Da Silva, Francisco Jose Lima Aragao, Luiz Alberto Colnago, Alan Carvalho Andrade, Daniela Matias De Carvalho Bittencourt, Pedro Ismael Da Silva Junior, Betulia De Morais Souto, Luisa De Moraes Madeira, Paulo Cesar Motta
-
Publication number: 20100311667Abstract: A compound of the formula I: R-A-Gly-His-B (I) wherein: A and B are independently of each other a L-lysine residue, a D-lysine residue, or a L- or D-lysine residue in which the NH2 group of the side chain comprises a modification, where-in said modification is (i) a replacement with a hydrogen, (ii) an acetylation, (iii) a benzoylation, or (iv) a palmitoylation; GIy is a glycine residue; His is a L- or D-histidine residue; R is CH3—(CH2)n—CO—, wherein n=2, 3, 4, 5, 6, 7 or 8; R? is a group of formula (II): N(Z)(Z?) (II) wherein: Z and Z? is hydrogen, a methyl group, an ethyl group, a phenyl group, an hexyl group, a decyl group or an hexadecyl group; or a racemate, an enantiomer or a diastereomer thereof, or mixtures thereof, or a salt thereof.Type: ApplicationFiled: June 30, 2008Publication date: December 9, 2010Applicant: Innovactiv Inc.Inventors: Michel Hocquaux, Estelle Loing, Philippe Bedos
-
Publication number: 20100298231Abstract: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.Type: ApplicationFiled: May 12, 2010Publication date: November 25, 2010Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventors: EBERHARD SCHNEIDER, Gregor Schurmann, Peter Wagner, Hong Wang
-
Publication number: 20100292153Abstract: The present invention provides a method of treating or preventing inflammation in a subject comprising administering to the subject an effective amount of a muramyl dipeptide (MDP).Type: ApplicationFiled: November 30, 2007Publication date: November 18, 2010Applicant: Department of Health and Human ServicesInventor: Warren Strober
-
Publication number: 20100286056Abstract: The present invention relates to the use of one or more tripeptides selected from the group consisting of NLys-Pro-ValC, NLys-Pro-ThrC and NpGLu-His-ProC for the reduction of oxidative stress. The above tripeptides are particularly useful for the treatment of a disease or damage caused by oxidative stress; such as vitiligo, scleroderma, necrosis, or erythema; furthermore, a disease or damage of the hair, like premature hair loss or premature formation of grey hair. Furthermore the invention relates the cosmetic use of the above tripeptides, in particular against skin aging. Further the invention relates cosmetic compositions containing at least one of said tripeptides.Type: ApplicationFiled: November 19, 2008Publication date: November 11, 2010Inventor: Markus Böhm
-
Publication number: 20100286055Abstract: Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for accelerating wound healing. Also provided is a method of accelerating wound healing, the method comprising providing a therapeutically effective amount of WNT3 A, or a therapeutically effective fragment or derivative thereof, to a site where wound healing is to be accelerated. The medicaments and methods of the invention may be of particular use in accelerating the healing of skin wounds.Type: ApplicationFiled: February 14, 2008Publication date: November 11, 2010Inventors: Mark W. J. Ferguson, Hugh Laverty, Nicholas Occleston, Sharon O'Kane, Kerry Nield
-
Publication number: 20100286040Abstract: This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and/or can be used to modulate the immune system of a subject.Type: ApplicationFiled: June 25, 2010Publication date: November 11, 2010Inventors: Laura L. Eggink, J. Kenneth Hoober
-
Publication number: 20100278759Abstract: The present invention relates to an oil-in-water emulsion topical delivery system comprising an oil phase; an aqueous phase; phenoxyethanol; an effective exfoliatingamount of a hydrophobic hydroxycarboxylic acid; a non-ionic emulsifier having an HLB of from about 7 to about 10; and at least one skin-supporting ordermatopharmaceutically active agent.Type: ApplicationFiled: February 8, 2007Publication date: November 4, 2010Inventor: Howard Murad
-
Publication number: 20100278756Abstract: The present invention relates to a peptide having the activity of insulin like growth factor-1 (IGF-1) and derived from IGF-1, a composition for improving skin conditions or treating a periodontal disease comprising the peptide. The IGF-1 mimicking peptides of this invention have identical functions or actions to natural-occurring IGF-1 and much better stability and skin permeation than natural-occurring IGF-1. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on the treatment, prevention and improvement of diseases or conditions demanding IGF-1 activities. In addition, the peptides of this invention can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.Type: ApplicationFiled: March 12, 2010Publication date: November 4, 2010Applicant: CAREGEN CO., LTDInventors: Yong Ji Chung, Young Deug Kim, Eun Mi Kim
-
Publication number: 20100279932Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.Type: ApplicationFiled: July 12, 2010Publication date: November 4, 2010Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, PETER AMSTRONG THOMPSON